Nanomedicine News RSS Feed - Nanomedicine

Magnetothermal Multiplexing of Nanomaterials Holds Promise for Targeted Drug Delivery

Magnetothermal Multiplexing of Nanomaterials Holds Promise for Targeted Drug Delivery

Magnetic nanoparticles don’t have to be "one size fits all." Instead, individual magnetic nanoparticles can be tailored in an array of differing sizes and compositions to allow for heating them separately by varying the frequency and amplitude of an external alternating magnetic field, MIT graduate student Michael G. Christiansen and colleagues show in a recent Applied Physics Letters paper. [More]
Non-Invasive, Molecular-Genetic Technique Using Nanoparticles for Imaging of Metastatic Cancer

Non-Invasive, Molecular-Genetic Technique Using Nanoparticles for Imaging of Metastatic Cancer

Bioluminescence, nanoparticles, gene manipulation – these sound like the ideas of a science fiction writer, but, in fact, they are components of an exciting new approach to imaging local and metastatic tumors. [More]
3DNA Nanotechnology Platform Provider, Genisphere, Closes $2 Million in Private Funding

3DNA Nanotechnology Platform Provider, Genisphere, Closes $2 Million in Private Funding

Genisphere LLC, provider of the 3DNA® nanotechnology platform, reported today it has closed $2 million in private funding from existing investors, including Corporate Fuel Partners, a New York fund. This round of fundraising will accelerate Genisphere's targeted drug delivery initiative, following key milestones including the company's demonstration of cell-specific (cytosolic and nuclear) delivery of drugs with functional intracellular effects without apparent toxicity. [More]
Novavax Begins Phase 2 Clinical Trial of RSV F-Protein Nanoparticle Vaccine

Novavax Begins Phase 2 Clinical Trial of RSV F-Protein Nanoparticle Vaccine

Novavax, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that enrollment has begun in a Phase 2 clinical trial of its respiratory syncytial virus F-protein nanoparticle vaccine candidate (RSV F Vaccine), in healthy women in the third trimester of pregnancy. [More]
Nanomedicine Company, Coldstream, Partners with CytImmune for CYT-6091 Phase II Trials

Nanomedicine Company, Coldstream, Partners with CytImmune for CYT-6091 Phase II Trials

Coldstream Laboratories, Inc., a provider of sterile drug product development and manufacturing services, has announced a partnership with CytImmune to manufacture CYT-6091 for injection in preparation for Phase II clinical trials. [More]
CeloNova’s COBRA PzF Coronary Stent System with Polyzene-F Nano-Thin Coating Found to be Safe

CeloNova’s COBRA PzF Coronary Stent System with Polyzene-F Nano-Thin Coating Found to be Safe

CeloNova BioSciences, Inc., today announced that positive First-in-Man (FIM) clinical trial results found its COBRA PzF™ coronary stent system with an advanced nano-thin coating of Polyzene®-F polymer to be a safe and effective routine interventional treatment for real-world and complex patients with heart disease. [More]
Encouraging Preclinical Results from Study of Celator’s CPX-351 for Acute Lymphoblastic Leukemia

Encouraging Preclinical Results from Study of Celator’s CPX-351 for Acute Lymphoblastic Leukemia

Celator Pharmaceuticals, Inc., a pharmaceutical company developing new and more effective therapies to treat cancer, today announced the publication of preclinical data in Pediatric Blood & Cancer that further characterize the therapeutic potential of lead compound CPX-351 in hematological malignancies and support its ongoing clinical testing in pediatric patients with ALL. CPX-351 is currently being studied in a pivotal Phase 3 clinical trial in older patients with high risk (secondary) AML. [More]
Immunotope Granted World-Wide License of CaPtivate's CaP Nanoparticle Technology

Immunotope Granted World-Wide License of CaPtivate's CaP Nanoparticle Technology

CaPtivate Pharmaceuticals LLC, a Pennsylvania-based biotechnology company developing calcium phosphate (CaP)-based nanoparticle drug and vaccine delivery technologies, announced today that the company has entered a License Agreement with Immunotope Inc., another Pennsylvania-based biotechnology company developing immunotherapy products for the treatment and prevention of viral infections and cancer. [More]
Blood-Cleansing Device Utilizes Modified Blood Proteins Coated on Magnetic Nanoparticles

Blood-Cleansing Device Utilizes Modified Blood Proteins Coated on Magnetic Nanoparticles

Things can go downhill fast when a patient has sepsis, a life-threatening condition in which bacteria or fungi multiply in a patient's blood -- often too fast for antibiotics to help. A new device inspired by the human spleen and developed by a team at Harvard's Wyss Institute for Biologically Inspired Engineering may radically transform the way doctors treat sepsis. [More]
IMBED to Advance Polymeric Nanofilm Wound Healing Technology with Investment from WISC Partners

IMBED to Advance Polymeric Nanofilm Wound Healing Technology with Investment from WISC Partners

Strategic operating capital fund, Wisconsin Investment and Strategic Capital Partners (“WISC Partners”), has made the lead investment in Imbed Biosciences (“IMBED”) in order to advance the development and commercialization of their promising wound healing technology. [More]